Search Details

Word: nih (lookup in dictionary) (lookup stats)
Dates: during 1990-1999
Sort By: most recent first (reverse)


Usage:

Matsuguchi's misconduct was "intentional falsification of data in two autoradiographs prepared for a presentation and in altering a print of an immunoblot of a paper in the journal [of the European Molecular Biology Organization]," according to Lyle W. Bivens, the director of the NIH Office of Research Integrity...

Author: By Douglas M. Pravda, | Title: NIH Cites Two Researchers For Misconduct | 12/12/1995 | See Source »

...government regulations require recipients of grants from the National Science Foundation (NSF) or the National Institutes of Health (NIH) to file a disclosure form with the Committee on Professional Conduct's subcommittee on conflicts of interest, according to Bertrand I. Halperin, Hollis professor of mathematics and natural philosophy and chair of the subcommittee...

Author: By Douglas M. Pravda, | Title: Conflicting Connections? | 11/1/1995 | See Source »

...Halperin says the forms apply only to those professors receiving NSF or NIH funds and not to all faculty...

Author: By Douglas M. Pravda, | Title: Conflicting Connections? | 11/1/1995 | See Source »

Other genetics experts argue that the time has come to re-evaluate the approach taken by most gene therapists, and perhaps even to redirect their efforts. Last spring Dr. Harold Varmus, head of the National Institutes of Health, appointed an independent committee of scientists to look into how the NIH spends its gene-therapy research dollars (some $200 million a year) and whether the government is getting its money's worth. "I've been a bit concerned that we weren't fulfilling the promise of gene therapy in any obvious way at this point," Varmus explains. "My intuition tells...

Author: /time Magazine | Title: HAS GENE THERAPY STALLED? | 10/9/1995 | See Source »

Some of this is unavoidable. Even the NIH's Varmus acknowledges the legitimate role commercial investment plays in moving gene therapy forward. The danger is that overreliance on commercial investors could change the kind of science that gets done. "The involvement of privately funded companies is already moving the focus away from rare genetic disorders," says Doris Zallen, a member of the NIH advisory panel that reviews gene-therapy trials for safety. Private investors tend to be more interested in diseases that affect large numbers of potential customers...

Author: /time Magazine | Title: HAS GENE THERAPY STALLED? | 10/9/1995 | See Source »

Previous | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 | 26 | 27 | 28 | 29 | 30 | 31 | Next